Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Janux Therapeutics
Biotech
Janux's T-cell engager makes waves, again, with new data drop
Among patients with heavily pretreated prostate cancer, all 16 patients who received JANX007 achieved a 50% decline in prostate-specific antigens.
Zoey Becker
Dec 3, 2024 11:40am
Janux's shares jump 130% following T-cell engager data drop
Feb 27, 2024 10:35am
Merck-partnered Janux hires CMO as its bispecifics near clinic
Jun 4, 2021 8:05am
Janux seeks $100M IPO on preclinical promise of bispecifics
May 21, 2021 6:55am
Janux raises $56M to take safer T-cell engagers into the clinic
Mar 3, 2021 8:00am
Janux pairs up with Merck for $1B-plus T-cell engager deal
Dec 18, 2020 9:50am
